Novocure Reports Third Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
JMP Securities Starts NovoCure Ltd. (NVCR) at Market Outperform
October 27, 2015 8:18 AM EDTJMP Securities initiated coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Market Outperform rating and a price target of $43.00.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $20.58 yesterday.
... MoreWedbush Starts NovoCure Ltd. (NVCR) at Outperform
October 27, 2015 7:28 AM EDTWedbush initiates coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Outperform rating and a price target of $30.00.
Analyst Tao Levy commented, " NovoCure is a rapidly emerging, commercial stage company whose flagship Tumor Treating Fields (TTFields) technology reverses tumor growth by disrupting cell... More
Novocure (NVCR) Reports Q3 Loss of $2.09/Share
October 26, 2015 4:14 PM EDTNovocure (NASDAQ: NVCR) reported Q3 EPS of ($2.09), versus ($1.45) reported last year. Revenue for the quarter came in at $8.95 million, versus $4.37 million reported last year.
Third Quarter 2015 Operating Statistics
354 prescriptions were received in the quarter, an... More